The Fox Focus Spring/Summer 2016 | Page 13

ANDREW KIST ON THE COMMUNITY Israel Robledo (left) and Steve DeWitte MJFF: What role will the patient voice play in the future of Parkinson’s research? Israel: The voice of the patient will be much stronger because that’s what happens when we come together to focus on a cure and the quality-of-life issues that impact people every day. We need treatments to let people live their lives. Steve: The more the patient’s voice is included in the research process, from conception of an idea to development of a treatment, the quicker the science will move forward. MJFF: What advice would you share with others interested in getting involved in PD public policy and advocacy efforts? ful. It takes time and patience, but when we develop our own personal message and stay true to it, our passion comes through. We’re committed to finding a cure. Steve: I invited a state legislator to a sup- port group. He looked around the room and saw his friends and neighbors who he didn’t know had Parkinson’s. He said, “When we’re looking at a bill related to Parkinson’s, I’ll think about my family, my friends and my neighbors and it’ll impact how I vote.” An advocate is someone who shares their story in order to make a difference to help themselves and others. Anybody can do it. Israel: Think through your passions, and Israel Robledo has served as Texas state director for the Parkinson’s Action Network. Steve DeWitte sits on the MJFF Patient Council. COULD SMART DEVICES... will allow researchers to investigate Parkinson’s disease, “off” episodes and the efficacy of APL-130277. develop a message to share with others. For example, my style is tenacious but respect- continued from page 2› Measuring Drug Impact with Smart Tools A small group of volunteers in the Cynapsus Phase III trial will use a wearable computing device and the Fox Insight smartphone application (developed by MJFF and Intel) to contribute data on movement and medication effect. The data will be securely collected, de-identified and evaluated by Intel, then stored in a cloud platform that “At this point, this is a proof-of-concept study testing feasibility and utility,” said Sherer. “Is it possible to capture this data easily? What can we learn from its analysis?” Depending on the results of pilots like this one, he adds, future studies may routinely make use of wearable devices and smartphone applications. SPRING/SUMMER 2016 13